Literature DB >> 1748552

Pharmacokinetic study of recombinant human epidermal growth factor in the anterior eye.

K Y Chan1, T D Lindquist, M J Edenfield, M A Nicolson, A R Banks.   

Abstract

This study investigated the pharmacokinetics of recombinant human epidermal growth factor (EGF) in the eyes of live rabbits and enucleated human eyes. After intracameral injection of 1.2 muCi (1.1 micrograms) of 125I-EGF into rabbit eyes, tissues in the anterior segment were analyzed for uptake of 125I-EGF after 1, 2, 4, and 24 hr. The half-life of EGF during the initial 4 hr was 1.3 +/- 0.6 hr (+/- the confidence limit at P = 0.05) in the cornea, 0.7 +/- 0.4 hr in the iris, 1.9 +/- 0.9 hr in the lens, and 0.6 +/- 0.5 hr in the aqueous humor (n = 18 for each tissue). Between 4-24 hr, the percent retention of EGF in the tissues (relative to the initial amount in respective tissue) is in the order of lens greater than cornea greater than iris greater than aqueous humor. The kinetics of EGF uptake by excised human corneas was determined by incubating the endothelial surface with 1.2 muCi/ml (100 ng/ml) of 125I-EGF for 4 hr at 37 degrees C or 4 degrees C. After 4 hr, the total amount of EGF accumulated in the corneas was 2.3 +/- 0.2 ng (+/- standard deviation; n = 6) at 37 degrees C, and 1.4 +/- 0.1 ng at 4 degrees C.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748552

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  2 in total

1.  Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA.

Authors:  Elissa Everton; Fatima Rizvi; Anna R Smith; Mitchell Beattie; Ying Tam; Norbert Pardi; Drew Weissman; Valerie Gouon-Evans
Journal:  Bio Protoc       Date:  2021-10-05

2.  Individualised computational modelling of immune mediated disease onset, flare and clearance in psoriasis.

Authors:  Fedor Shmarov; Graham R Smith; Sophie C Weatherhead; Nick J Reynolds; Paolo Zuliani
Journal:  PLoS Comput Biol       Date:  2022-09-30       Impact factor: 4.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.